Adlai Nortye Ltd
ANL1.486USD
+0.036+2.50%
시장 운영 시간 （ET）시세는 15분 지연됩니다
164.52M시가총액
손실P/E TTM
자세한 내용은 Adlai Nortye Ltd 회사
Adlai Nortye Ltd is a Cayman Island-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
회사 정보
종목 코드 ANL
회사 이름Adlai Nortye Ltd
상장일Sep 29, 2023
CEOMr. Lars Erik Birgerson
직원 수123
유형Depository Receipt
회계 연도 종료Sep 29
주소c/o PO Box 309
도시GRAND CAYMAN
증권 거래소NASDAQ Global Market Consolidated
국가Cayman Islands
우편 번호KY1-1104
전화18482307430
웹사이트https://www.adlainortye.com/
종목 코드 ANL
상장일Sep 29, 2023
CEOMr. Lars Erik Birgerson
회사 임원
이름
이름/직위
직위
주식 보유
변동
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Kaiyang Tang
Dr. Kaiyang Tang
Senior Vice President, Global Head of Clinical Operations
Senior Vice President, Global Head of Clinical Operations
--
--
이름
이름/직위
직위
주식 보유
변동
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 24
마지막 업데이트: Sat, May 24
주주
주주 유형
주주
주주
비율
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Cantor Fitzgerald, L.P
0.13%
Millennium Management LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.23%
주주
주주
비율
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Cantor Fitzgerald, L.P
0.13%
Millennium Management LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.23%
주주 유형
주주
비율
Corporation
14.25%
Investment Advisor
0.14%
Hedge Fund
0.04%
Other
85.57%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
8
4.51M
14.43%
+4.45M
2025Q1
8
4.51M
14.43%
+4.45M
2024Q4
5
2.23M
7.14%
+2.17M
2024Q3
5
2.24M
7.16%
+2.18M
2024Q2
5
2.23M
7.15%
+2.17M
2024Q1
5
2.23M
7.15%
+2.17M
2023Q4
5
2.24M
7.16%
+2.19M
2023Q3
3
48.25K
0.15%
+48.25K
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Nortye International Ltd
2.33M
7.47%
+2.33M
--
Dec 31, 2024
Nortye Talent Ltd
349.27K
1.12%
+349.27K
--
Dec 31, 2024
Cantor Fitzgerald, L.P
40.31K
0.13%
--
--
Mar 31, 2025
Millennium Management LLC
11.56K
0.04%
-5.03K
-30.31%
Mar 31, 2025
UBS Financial Services, Inc.
4.67K
0.01%
+4.67K
+467400.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
19.00
0%
+19.00
--
Mar 31, 2025
Qube Research & Technologies Ltd
--
0%
-88.00
-100.00%
Sep 30, 2024
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
